Related references
Note: Only part of the references are listed.Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Markus Ruhnke et al.
MYCOSES (2020)
COVID-19 associated pulmonary aspergillosis
Philipp Koehler et al.
MYCOSES (2020)
Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden
Lefteris Floros et al.
BMC INFECTIOUS DISEASES (2019)
ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children
A. Warris et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Effective healthcare cost-containment policies: A systematic review
Niek Stadhouders et al.
HEALTH POLICY (2019)
Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016
S. M. Heimann et al.
JOURNAL OF HOSPITAL INFECTION (2019)
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
A. J. Ullmann et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review
Matteo Bassetti et al.
INFECTIOUS DISEASES AND THERAPY (2018)
Invasive mould infections in the ICU setting: complexities and solutions
Matteo Bassetti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
Thomas F. Patterson et al.
CLINICAL INFECTIOUS DISEASES (2016)
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan A. Maertens et al.
LANCET (2016)
Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial
David Horn et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole
S. M. Heimann et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2015)
The Association Between Health Care Quality and Cost A Systematic Review
Peter S. Hussey et al.
ANNALS OF INTERNAL MEDICINE (2013)
Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes
John W. Baddley et al.
BMC INFECTIOUS DISEASES (2013)
Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2008)
Invasive Aspergillosis - Epidemiology, diagnosis and management in immunocompromised patients
Georg Maschmeyer et al.
DRUGS (2007)
Share Paper
